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Abstract
Background: The growth of new blood vessels in adult life requires the initiation of endothelial
cell migration and proliferation from pre-existing vessels in addition to the recruitment and
differentiation of circulating endothelial progenitor cells. Signals emanating from growth factors and
the extracellular matrix are important in regulating these processes.
Results: Here we report that fibronectin (FN) and vitronectin (VN) modulate the responses of
endothelial cells to HGF (Scatter Factor), an important pro-angiogenic mediator. Novel binding
sites for HGF were identified on both FN and VN that generate molecular complexes with
enhanced biological activity and these were identified in the supernatants of degranulated platelet
suspensions implicating their release and formation in vivo. In the absence of co-stimulation with an
ECM glycoprotein, HGF could not promote endothelial cell migration but retained the capacity to
induce a proliferative response utilising the Map kinase pathway. Through promoting Met-Integrin
association, HGF-FN and HGF-VN complexes coordinated and enhanced endothelial cell migration
through activation of the PI-3 kinase pathway involving a Ras-dependent mechanism whereas a Ras-
independent and attenuated migratory response was promoted by co-stimulation of cells with HGF
and a non-binding partner ECM glycoprotein such as collagen-1.
Conclusions:  These studies identify a novel mechanism and pathway of HGF signalling in
endothelial cells involving cooperation between Met and integrins in a Ras dependent manner.
These findings have implications for the regulation of neovascularization in both health and disease.
Background
The generation and repair of blood vessels in adult life
requires the regulation of endothelial cell survival, migra-
tion, proliferation and their differentiation from lineage-
committed progenitors by the coordinated action of sev-
eral classes of vaso-active agents including growth factors,
cytokines, and the extracellular matrix (ECM) [1-4]. Eluci-
dating the molecular mediators of these signals and their
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mechanism of action is vital to understanding the fine reg-
ulation of neo-vessel development and maintenance.
There is growing evidence pointing to a close collabora-
tion between growth factors and the ECM in several bio-
logical processes including vasculogenesis and post-natal
revascularization. Studies have shown that the response of
cells to growth factors such as vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF) and
epidermal growth factor (EGF) are potentiated by integrin
ligation to specific ECM glycoproteins [5-8]. In a previous
report, we showed that VEGF-induced endothelial cell
migration was augmented by fibronectin (FN) [9]. We
also presented evidence that the VEGF/VEGFR-2 pathway
is coupled to the integrin α5β1 through a mechanism
involving the promotion of an integrin α5β1-VEGFR-2 sig-
nalling moiety generated as a consequence of receptor
ligation by a VEGF-FN complex. These events promoted
the sustained activity of Erk kinase, which was coupled to
the migratory response. More recently, we presented data
demonstrating that FN significantly enhanced VEGF-
mediated migration of CD34+ cells and their differentia-
tion into endothelial cells [10]. In addition to the VEGF
pathway, in vitro studies have highlighted the importance
of hepatocyte growth factor (HGF) as a pro-angiogenic
mediator. HGF, also termed scatter factor, has a well-
established role in tumourogenesis but may be an impor-
tant mediator of neovascularization since studies show
that HGF induces the expression of VEGF in endothelial
cells in vitro and that HGF synergises with VEGF to pro-
mote capillary-tube assembly in collagen matrices
[11,12]. In addition, neovascularization in the rat cornea
was also elevated by co-administration of HGF and VEGF
compared to either growth factor in isolation [11]. The
emerging significance of HGF as a pro-angiogenic media-
tor was further highlighted by a recent study of a large
cohort of patients (1090 patients, CAPTURE trial) with
acute coronary syndromes and identified serum levels of
HGF as a positive indicator of patients' prognosis associ-
ated with a significantly lower event rate and increased
collateralization of the target vessel [13]. Although the
pro-angiogenic effects of HGF are known, the detailed
mechanism of HGF action on the vascular cells, including
the identity of intracellular mediators remains poorly
understood.
In the present work we show that HGF forms a specific
physical complex with FN and VN and that these com-
plexes are present in degranulated platelet suspensions
implicating a putative role in vivo. Significantly, we show
that HGF-FN and HGF-VN molecular complexes induce a
unique and enhanced intracellular signal employing Ras,
thereby highlighting an important mechanism of growth
factor receptor tyrosine kinase and integrin cooperation in
promoting pro-angiogenic responses.
Results
Identification of novel HGF binding domains on FN and VN
We recently identified binding domains on FN for VEGF,
which played an important role in promoting the activity
of VEGF [9]. Since HGF is also an important angiogenic
factor, experiments were designed to establish whether
HGF had specific ECM binding partners. Using a solid
phase assay, we measured the binding of 125I-labelled
HGF to a variety of ECM molecules immobilized on plas-
tic wells. As shown in Fig. 1A, 125I-labelled HGF bound to
both FN and VN specifically with residual binding
observed to either collagen-1 or laminin. Further experi-
ments were performed to locate the HGF binding site on
the FN molecule using purified FN proteolytic fragments
immobilised onto the polystyrene microtiter wells. In
these experiments 125I-labelled HGF bound to the 70 kDa
N-terminal fragment and the 40 kDa C-terminal frag-
ment. No significant binding was observed to the 120 kDa
fragment that harbours the internal cell binding domain
(Fig. 1B). To further analyse the association between HGF
and FN, the interaction of HGF with the FN fragments was
measured in real time by surface plasmon resonance anal-
ysis (SPR). As shown in Fig. 1C &1D, HGF bound to the
70 kDa N-terminal FN fragment immobilized on the sen-
sor chip in a specific and saturable manner with a Kd of
approximately 300 ± 93 nM for a one-site model. The data
shown in Fig. 1D could be applied to a two-site model
with equal probability showing Kd values for the high and
low affinity sites of 15 nM ± 2 nM and 4 µM respectively.
HGF binding to the 40 kDa fragment could not be meas-
ured directly by SPR, as immobilization of the 40 kDa
fragment on the sensor chip appeared to mask the HGF
binding site (data not shown).
Platelets release HGF complexed to FN and VN
To establish whether HGF-FN and HGF-VN molecular
complexes occur in vivo we examined platelets, a rich
source of growth factors, for the presence of these com-
plexes. Washed human platelet suspensions were stimu-
lated with thrombin (1 U/ml) to promote degranulation
and the derived supernatants were immunoprecipitated
with antibodies directed to FN or VN. The resulting
immune complexes were analysed for co-precipitation of
HGF (Fig. 1E &1F). Immunoprecipitation of FN from
thrombin-stimulated platelet supernatants resulted in sig-
nificant co-precipitation of HGF (Fig. 1E). In contrast,
minimal levels of HGF was observed in samples derived
from unstimulated platelet supernatants or from samples
derived from thrombin-stimulated platelet supernatants
when an isotype-matched control antibody was employed
in the experiment. Probing of the same blot with antibod-
ies to FN confirmed that the primary precipitation of FN
was responsible for the co-precipitation of HGF (Fig. 1E,
lower panel). In a parallel experiment, immunoprecipita-
tion of VN also co-precipitated HGF to a similar if notBMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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Identification of HGF Binding Domains on FN and VN and the presence of HGF-FN and HGF-VN complexes in platelet  supernatants Figure 1
Identification of HGF Binding Domains on FN and VN and the presence of HGF-FN and HGF-VN complexes in 
platelet supernatants. Panel A-Plastic wells coated with various matrix proteins or BSA (10 µg/ml) were incubated with 125I-
labelled HGF to equilibrium and then washed and counted in a γ-counter. Panel B-Plastic wells were coated with FN and FN 
derived proteolytic fragments or BSA. 125I-labelled HGF was incubated in these wells to equilibrium binding, washed and the 
bound HGF levels determined using γ-counter. Panels C &D-Binding of HGF to FN 70 kDa fragment in real time by SPR. Panel 
C-Real time binding isotherms of increasing concentrations of HGF (0, 16.5, 31.25, 62.5, 125, 188, 250, 315, 375, 500 nM)with 
association and dissociation phases for a single representative experiment with the arrows indicating injection start and finish. 
Panel D-The data from panel C is plotted as a function of HGF concentration (30–500 nM). Inset shows the data analysed by 
the method of Scatchard showing a single binding site with a Kdapp = 300 nM. The data could also fit equally well to a two-site 
model (see text for details). n = 3. Panel E-Platelet suspensions (20.0 × 108/ml) were stimulated with either saline (-) or 1 U/ml 
thrombin (+) for 5 min at room temperature to allow degranulation. Cellular and membranous material was cleared by centrif-
ugation (100,000 × g) and the supernatants were immunoprecipitated with monoclonal antibodies to FN or an isotype matched 
control reagent (control IgG). Immune complexes were analysed by SDS-PAGE and Western blotting probing with an antibody 
to HGF (Santa Cruz). The blot was stripped and re-probed with antibodies to FN to confirm the specificity of the primary 
immunoprecipitation step. Panel F-Supernatants derived from thrombin-stimulated platelets were immunoprecipitated with 
antibodies with specificity for either FN, VN or an isotype matched control reagent. The immune complexes were analysed as 
in panel E. Lower panel shows the same blot stripped and re-probed with a monoclonal antibody to VN to confirm the primary 
precipitation. Blots were developed by chemiluminescence. The data shown are representative blots of experiments repeated 
three times.BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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greater extent than FN (Fig. 1F). These experiments dem-
onstrate that HGF is released from platelets and is found
in the form of soluble molecular complexes with both FN
and VN, confirming the results of the ligand binding stud-
ies in vitro.
HGF-Induced endothelial cell migration is dependent upon 
co-stimulation with ECM
We next sought to determine whether the responses of
endothelial cells to HGF could be modulated by its ECM
binding partners. In cell migration assays, human micro-
vessel endothelial cells (HMVEC) were incubated with an
optimal concentration of HGF alone or in combination
with fixed concentrations of FN, VN or collagen-1 (Fig.
2A). Significantly, little or no endothelial cell migration
above basal levels (control) was observed when cells were
stimulated with HGF (10 ng/ml) in the absence of ECM.
A moderate migratory response of endothelial cells to
HGF was observed in the presence of collagen-1 (non-
HGF binding ECM), which was less than 2-fold above
basal levels. When HGF was co-administered with either
FN or VN, endothelial cell migration was significantly
enhanced by 4–5 fold. The differences in magnitude of the
migration in the presence of these ECM glycoproteins was
not related to variable degrees of cell adhesion upon the
transwell filters as HGF-stimulated endothelial cells
adhered equally well to ECM glycoprotein-coated tran-
swells (Fig. 2B). The migratory response to HGF was dose
responsive with a maximal response observed at a concen-
tration of 10–20 ng/ml (data not shown). In addition, a
negligible migratory response was observed when
HMVEC were stimulated with these ECM molecules in the
absence of HGF consistent with our previous report (data
not shown, ref .9).
To further characterize the degree and identity of integrin
involvement in the observed migratory response, we
investigated the consequences of blocking integrin recep-
tors on HMVEC with specific integrin antibodies prior to
HGF-ECM stimulation. Antibodies directed to the integrin
α5β1 completely inhibited HGF-FN-induced endothelial
migration (Fig. 2C). In contrast, an antibody with specifi-
city for the αv-subunit (LM142) had no inhibitory effect
on endothelial cell migration. However, antibodies to the
αvβ3 integrin (LM609) did inhibit endothelial cell migra-
tion to HGF-FN by 20% suggesting an ancillary role for
this integrin in mediating HGF-FN responses. When
endothelial cell migration was induced by HGF-VN com-
plexes, the integrin dependence shifted as expected (Fig.
2D). Under these conditions endothelial cell migration
was predominantly dependent on αv-integrins for medi-
ating the migratory signal with some apparent involve-
ment of the integrin α5β1 (approximately 30%). This latter
effect may be a consequence of integrin signal cross-talk
(transdominant integrin regulation), as reported previ-
ously [14,15]. These experiments demonstrate that for
HMVEC, HGF induced cell migration is dependent upon
the ligation of integrins by ECM molecules.
Met associates with αvβ3 and α5β1 integrins
Previous work [5-7,9] has demonstrated that the physical
association of growth factor receptor tyrosine kinases and
integrins promote enhanced cellular responses. We, there-
fore, postulated that the elevated cell migration induced
by HGF-FN and HGF-VN in the present study could be
due to a signalling mechanism involving the physical
association between Met and integrins on endothelial
cells. As shown in Fig. 3A, endothelial cell lysates derived
from samples exposed to collagen-1, FN or VN, in the
presence of HGF, when immunoprecipitated with anti-
bodies to integrins α2β1, α5β1 and αvβ3 respectively, pre-
dominantly co-precipitated Met with the integrins α5β1
and  αvβ3. In contrast, Met co-precipitation with the
integrin α2β1 was minimal for lysates derived from cells
stimulated with HGF and collagen-1. The level of Met
expression in these samples was not altered by treatment
of the cells with various combinations of HGF and ECM
molecules (Fig. 3A lower panel) discounting the possibil-
ity that the differences in the level of Met co-precipitation
was due to differences in the expression levels of its anti-
gen. In the absence of HGF, co-precipitation of Met with
the integrins α5β1 and αvβ3 was minimal despite the pres-
ence of the ECM glycoprotein, indicating that ligation of
the integrin with its cognate ligand was not sufficient to
induce an association with Met.
To elucidate the role of Met activation in the formation of
the Met-integrin signalling complex, endothelial cells
were treated with HGF in the absence of ECM glycopro-
tein and with HGF-FN and HGF-VN complexes and the
kinetics of Met tyrosine phosphorylation investigated
(Fig. 3B). These experiments demonstrated that HGF in
the absence of ECM glycoprotein could activate Met tran-
siently with a strong signal present at 15 min but absent at
1 hour. In contrast, cells stimulated with HGF-FN and
HGF-VN showed strong activation of Met at 15 min,
which was sustained at 1 hour and was evident, although
reduced, at 2 hours post-stimulation. Cell lysates derived
from samples stimulated for 15 mins were also assessed
for the presence of a Met-integrin complexes. As shown in
Fig. 3C, HGF in the absence of FN or VN did not promote
a significant association of Met with the integrins α5β1 or
αvβ3. However, cells treated with HGF-VN and HGF-FN
for 15 min contained significant levels of Met in a physical
association with these integrins. These studies show that
Met activation by HGF is insufficient to promote a physi-
cal association with integrins.BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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HGF binding domains on FN and VN promote enhanced 
intracellular signals
We next investigated whether the association of Met with
integrins modulated HGF/ECM-induced intracellular sig-
nalling, focussing on the ERK and the PI-3 kinase path-
ways. Analysis of the phosphorylation kinetics of Erk-1/2
in response to HGF alone or HGF/ECM combinations
showed distinct patterns of activation (Fig. 4A). With HGF
alone, Erk 1/2 phosphorylation showed kinetics with a
peak signal at 60 min post-stimulation and significant
reduction by 120 min although phosphorylation was still
apparent. A distinct activation profile was observed when
Effect of ECM molecules on HGF induced Endothelial cell migration Figure 2
Effect of ECM molecules on HGF induced Endothelial cell migration. Panel A-Dye-loaded HMVEC suspensions (9 × 
104/ml) were treated with HGF (10 ng/ml) in the presence or absence of ECM molecules, FN or VN or collagen-1 in a modified 
Boyden chamber assay. Migration of cells was measured at 3 hours. The data is presented as relative migration with the migra-
tory response presented as ratio to the basal migration in the absence of stimulus. Panel B-The levels of cell adhesion to Fluor-
blok transwell filters coated with either poly-L-lysine (PLL) or the various ECM glycoproteins was determined. Dye loaded 
HMVEC (105 cells) were treated with HGF (10 ng/ml) for 30 min prior to application to upper chamber of the transwell. Fol-
lowing extensive washes the number of adherent cells was determined using a fluorescence plate reader. The role and identity 
of integrins mediating the migration response in cells stimulated with HGF and FN (panel C) and HGF and VN (panel D) was 
demonstrated by the pre-treatment of HMVEC suspensions with anti-integrin monoclonal reagents (10 µg/ml) with specificity 
for integrins α5β1 (JBS5), αvβ3 (LM609) and αvβ5 (LM142) for 30 min at room temperature prior to application into the upper 
transwell chamber. The data is presented as specific migratory response in fluorescence units with the basal migration sub-
tracted from the total migratory response. (n = 2).BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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Association of Met with integrins is driven by HGF-FN and HGF-VN complexes Figure 3
Association of Met with integrins is driven by HGF-FN and HGF-VN complexes. Panel A-HMVEC (1 × 106 /ml) were 
seeded onto collagen-1, FN or VN coated plastic wells and were stimulated with either saline or HGF (10 ng/ml) for 60 min at 
room termperature. Cells were lysed and the corresponding lysates (500 µg protein) were immunoprecipitated with antibod-
ies to integrins α2β1 (lanes 1 & 4), αvβ3 (lanes 2 & 5) and α5β1 (lanes 3 & 6). Immunocomplexes were analysed by SDS-PAGE 
and Western blotting probing with an anti-Met antibody using chemiluminescence detection (top panel). The bottom panel 
shows the antigen levels of Met in the corresponding cell lysates after analysis by SDS-PAGE (40 µg/lane) and Western blotting 
probing with an antibody to Met were essentially unaltered during the duration of the experiment. Panel B-HMVEC (5 × 106) 
were stimulated with HGF or HGF-FN or HGF-VN complexes at the indicated time periods at room temperature. Cells were 
lysed and immunoprecipitated with a polyclonal antibody to phosphotyrosine Met and the immune complexes analysed by 
SDS-PAGE and Western blotting using a monoclonal antibody to Met. The Met antigen was detected using chemiluminescence. 
Panel C-HMVEC (5 × 106) were stimulated with HGF or HGF-FN or HGF-VN complexes for 15 minutes at room temperature. 
Cells were lysed and the lysates immunoprecipitated with monoclonal antibodies to the integrins α5β1 and αvβ3 and the 
immune complexes analysed by SDS-PAGE and Western blotting probing with a polyclonal antibody to Met.BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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HGF-FN and HGF-VN complexes augment HMVEC migration via the PI3 kinase pathway Figure 4
HGF-FN and HGF-VN complexes augment HMVEC migration via the PI3 kinase pathway. Panel A-HMVEC sus-
pensions (1 × 106/ml) were stimulated with HGF (10 ng/ml) in the absence of ECM molecules or in the presence of collagen-1, 
FN or VN (2 µg/ml) for varying time intervals (2–120 min) at room temperature. The reaction was stopped by rapid centrifu-
gation and lysis of the cell pellet. Samples of cell lysate were analysed by SDS-PAGE and Western blotting probing with an anti-
body with specificity for phosphorylated Erk 1/2 (top panel). The blots were reprobed with an antibody to Erk 2 (bottom 
panel). Panel B-The samples from panel A were also probed simultaneously with an antibody with specificity for phosphorylated 
Akt (top panel) and these blots were stripped and re-probed with an antibody to Akt. Visualization was by chemiluminescence. 
Panel C &D-Effect of inhibitors on HMVEC migration in response to HGF-FN and HGF-VN respectively. The data is a repre-
sentative experiment using triplicate samples which was performed three times giving essentially similar results.BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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cells were stimulated with HGF and collagen-1 (non-HGF
binding ECM), with Erk 1/2 levels peaking at 30 min and
returning to near basal phosphorylation levels by 120
min. However, stimulation of endothelial cells with either
HGF-FN or HGF-VN complexes promoted a rapid but sus-
tained phosphorylation of Erk 1/2 with levels near maxi-
mal at 120 min post-stimulation. Analysis of the
activation of the PI-3 kinase pathway was assessed by
measurement of the phosphorylation status of Akt/PKB
on Ser473 (Fig. 4B). Interestingly, both distinct levels and
kinetics of Akt phosphorylation were observed in these
samples. When endothelial cells were stimulated with
HGF in the absence of ECM co-stimulation, little phos-
phorylation of Akt above basal levels was observed. How-
ever, when cells were treated with HGF plus collagen-1,
Akt phosphorylation was rapidly detected at 5 min and
peaked at 30 min with significant reduction by 120 min.
In contrast, with cells treated with either HGF-FN or HGF-
VN complexes, Akt phosphorylation kinetics appeared to
mirror Erk 1/2 phosphorylation kinetics implying a com-
mon regulatory mechanism for both pathways. As with
Erk 1/2 phosphorylation, Akt phosphorylation peaked by
30 min post stimulation and this level of activation was
sustained even at 120 min. Significantly, Akt phosphor-
ylation levels in these samples were elevated approxi-
mately 3-fold, (assessed by densitometry) compared with
the levels in observed in cells stimulated with HGF plus
collagen-1 (data not shown).
HGF/ECM-Induced endothelial migration is coupled to the 
PI-3 kinase pathway
To determine the intracellular pathway(s) that were cou-
pled to the migratory response, HMVECs were treated
with specific inhibitors of MEK and PI-kinase. In cell
migration assays, LY294002 but not U1026 inhibited
endothelial cell migration induced by HGF-FN (Fig. 4 C)
and HGF-VN (Fig. 4 D), clearly demonstrating that the PI-
3 kinase pathway was predominantly coupled to the
migratory response and not the Map kinase pathway.
Other inhibitors of potential down stream effectors were
also tested. HGF-FN stimulated cells pre-treated with PP1,
U73122, and piceatannol showed maximal migratory
responses indicating that Src, PLCβ and Syk were not com-
ponents of the migratory signal (data not shown).
HGF-Induced endothelial proliferation is coupled to the 
Erk-pathway
The effect of the co-administration of ECM molecules
with HGF on endothelial cell proliferation was also inves-
tigated. In contrast to cell migration, HGF, in the absence
of ECM molecules, induced a significant proliferative
response (Fig. 5A). However, in the presence of FN or VN,
HGF-induced endothelial proliferation was enhanced
compared to HGF alone or in combination with collagen-
1. As with the migratory response, endothelial cell prolif-
eration was dose responsive to HGF with an observed
maximal response at a concentration of 10–20 ng/ml
(data not shown). Chemical inhibitors were then used to
determine the signalling pathways involved in HGF-
induced endothelial cell proliferation. In these studies,
the MEK inhibitor, U1026 significantly impaired HGF-
induced endothelial proliferation (50–80% inhibition)
irrespective of co-stimulation with or without ECM mole-
cules. This suggests that unlike migration, which was
shown above, to be PI-3 kinase dependent, the Erk-path-
way plays an important role in mediating HGF-induced
endothelial cell proliferation. While both LY294002 and
FPT-III blocked HMVEC proliferation, this appeared to be
due to apoptosis (data not shown). This observation is
consistent with the role of PI-3 kinase in promoting cell
survival and a role for Ras in regulating PI-3 kinase in
these cells [16,17].
Ras is a specific, upstream regulator of Erk and PI-3 kinase 
pathways in cells stimulated with HGF-FN and HGF-VN 
complexes
The data shown above indicate that HGF-induced
endothelial cell migration and proliferation were medi-
ated by PI-3 kinase and Erk pathway respectively. We next
investigated the role of Ras in regulating these two path-
ways induced by HGF-FN and HGF-VN complexes. Since
Ras is a well-documented regulator of p85 PI-3 kinase and
Erk and as well as a down stream effector of both the Met
and integrin receptors, we assessed the activation status of
Ras by measuring the comparative levels of GTP-loaded
Ras after endothelial cells were stimulated with HGF in
the presence and absence of ECM molecules (Fig. 6A
&6B). Endothelial cells stimulated with HGF alone
showed high levels of GTP-Ras at 60 min post-stimulation
and this was sustained even at 120 min (Fig. 6A). In con-
trast, cells co-stimulated with HGF and collagen-1 showed
activation of Ras at 60 min post-stimulation but to a sig-
nificantly lower degree (approx 50% compared to HGF
alone Fig. 6B), with the signal diminished by 120 min.
With HGF-FN and HGF-VN co-stimulation, GTP-Ras lev-
els were more than two-fold higher than observed when
cells were co-stimulated with HGF-collagen-1 (Fig. 6B).
Significantly, GTP-Ras levels were sustained at 120 min
consistent with the observations of the activation profiles
for the MAP kinase and PI-3 kinase pathways. These stud-
ies suggested that inhibiting Ras in cells stimulated with
HGF-FN and HGF-VN complexes would exhibit reduced
migration responses. To test this hypothesis, cells were
treated with the membrane permeable farnesyltransferase
inhibitor FPT-III, which inhibits Ras function as a conse-
quence of the loss of membrane localization in the
absence of farnesylation. Upon stimulation with HGF-FN,
endothelial cells treated with FPT-III (100 µM) showed lit-
tle activation of Ras following HGF-FN stimulation
compared to basal levels in unstimulated cells (Fig. 7A).BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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In comparison, pre-treatment of cells with the geranylger-
anyl transferase inhibitor GGTI (2 µM) had little
inhibitory effect on HGF-FN induced Ras activation. The
effect of these inhibitors was tested in endothelial migra-
tion assays. Endothelial cells pre-treated with FPT-III dis-
played a profound reduction in cell migration of 50% and
73% when stimulated with HGF-FN and HGF-VN com-
plexes respectively compared to cells pre-treated with
GGTI (Fig. 7B). In contrast, FPT-III had little inhibitory
effect on migration induced by HGF plus collagen-1 indi-
cating that Ras has no significant role in the regulation of
the migratory signal with this stimulus.
To further characterise the role of Ras in regulating
endothelial cell responses to HGF/ECM, the effect of the
FPT-III inhibitor on the phosphorylation levels of Erk 1/2
and Akt was investigated. In cells stimulated with HGF
alone, Erk 1/2 was activated and significantly inhibited by
the FPT-III inhibitor and to a lesser extent by GGTI (Fig.
8A). A similar inhibitory profile was observed for cells
stimulated with HGF-FN (Fig. 8A) and HGF-VN (not
shown). In contrast, cells stimulated with HGF and colla-
gen-1 showed no apparent reduction in Erk 1/2 phospho-
rylation levels when pre-treated with the FPT-III inhibitor
suggesting little involvement of Ras in the activation of
Erk 1/2. These samples were also assessed for Akt phos-
phorylation as an indication of PI-3 kinase activity. Con-
sistent with our observations, stimulation of HMVEC with
HGF in the absence of ECM did not lead to a significant
activation of Akt (Fig. 8B). However, in the presence of
collagen, Akt activation was observed but this was not
affected by pre-treatment of the cells with FPT-III imply-
ing that Ras was not an upstream regulator of the activa-
tion of PI-3 kinase. In contrast, HGF-FN complexes
HGF induced HMVEC proliferation requires the Map kinase pathway Figure 5
HGF induced HMVEC proliferation requires the Map kinase pathway. Panel A-HMVEC in MCDB-131 medium was 
plated on poly-D-lysine coated 48-well plates at a density of 2.5 × 103 cells/well and were stimulated with HGF (10 ng/ml) in 
the presence and absence of ECM molecules FN, VN or collagen-1. Basal proliferation was measured with cells treated with 
non-supplemented medium. Cell numbers were quantified 48 hours post-stimulation using CyQuant reagent. Data is presented 
as cell numbers with the increase of proliferation of HGF-FN and HGF-VN treated samples significant compared with cells 
treated with HGF alone as determined by a one-way ANOVA (p < 0.05) n = 3. Panel B-HMVEC were plated onto poly-D-lysine 
coated wells (1 × 104/well) overnight in supplemented medium. Cells were then incubated with medium comprising 0.1% FBS 
plus HGF (20 ng/ml) in the presence or absence of ECM proteins (10 µg/ml) as shown containing no inhibitor (white bars) or 
the MEK inhibitor U1026 (10 µM, black bars). Cells numbers were quantified after a further 48 h using CyQuant reagent.BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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promoted a 3-fold enhancement of Akt phosphorylation
and this was inhibited by approximately 50 % by treating
the cells with FPT-III (Fig. 8B). These observations suggest
that the inhibition of Ras activation reduces the activation
of PI-3 kinase for cells stimulated with HGF-FN com-
plexes and not cells stimulated with HGF and collagen-1.
The data would therefore predict that when HMVEC are
stimulated with HGF-FN and HGF-VN complexes, specific
integrins are utilized to recruit Ras, which in turn would
regulate the activation of PI-3 kinase. To test this hypoth-
esis, we immunoprecipitated integrins α5β1 and α2β1
from cells stimulated with HGF-FN and HGF with colla-
gen-1 respectively and analysed these integrin immune
complexes for the co-precipitation of Ras. High levels of
Ras was specifically associated with α5β1 immune com-
plexes and this appeared be independent of HGF stimula-
tion. Little or no Ras was co-precipitated with the integrin
α2β1 (Fig. 8C).
Discussion
The major finding of the present report is that HGF-
induced endothelial cell responses are significantly
augmented through the formation of molecular
complexes between this growth factor and the ECM glyc-
oproteins FN and VN. The significance of this finding is
highlighted by the observation that HGF-induced
endothelial cell migration, a PI-3 kinase coupled
response, did not occur in the absence of additional sig-
nals originating from the ECM. However, HGF-induced
endothelial cell proliferation was evident in the absence
Enhanced and sustained activation of Ras by HGF-FN and HGF-VN Complexes Figure 6
Enhanced and sustained activation of Ras by HGF-FN and HGF-VN Complexes Panel A-Kinetic GTP-Ras pull down 
analysis. HMVEC suspensions (3 × 106/ml) were stimulated with HGF (10 ng/ml) in the absence and presence of ECM mole-
cules (2 µg/ml) as shown for 5, 60 and 120 min at room temperature. Lane Rest. represents resting (unstimulated) levels of 
GTP-Ras. Cells were pelleted and lysed in cold MLB buffer (see methods). Samples of cell free lysates were incubated with of 
RBD-Sepharose and then analysed by SDS-PAGE and Western blotting probing for Ras. Visualization was by chemiluminines-
cence using a Kodak imaging station. Panel B-The levels of GTP-Ras at the 60 min time point from the gel shown in panel A 
were quantified by densitometric analysis using ImageQuant software (Kodak).BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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HGF-FN and HGF-VN induced HMVEC migration is Ras dependent Figure 7
HGF-FN and HGF-VN induced HMVEC migration is Ras dependent. Panel A-GTP-Ras pull down assay showing the 
affects of FPT III (100 µM) and GGTI (2 µM) inhibitors upon GTP-Ras levels. HMVEC suspensions (3 × 106/ml) were pre-
treated with FPT III and GGTI inhibitors for 45 min at room temperature prior to stimulation with HGF-FN complexes for 60 
min at room temperature. Samples were analysed as mention in the legend to Fig 2. Panel B-Effect of Ras inhibition upon cell 
migration. Calcein M loaded HMVEC suspensions (1 × 105/ml) were pre-treated with the inhibitors as mentioned above prior 
to application to the top chamber of the transwell filter. Cells were stimulated with HGF plus ECM proteins (placed in the bot-
tom chamber) as shown. Cell migration was measured at 3 hours post stimulation using a fluorescence plate reader. The data 
is shown as relative migration and is the combined data from two independent experiments with sample wells in triplicate.BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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HGF-FN Induced Activation of Map Kinase and PI-3 Kinase Pathways is Ras dependent Figure 8
HGF-FN Induced Activation of Map Kinase and PI-3 Kinase Pathways is Ras dependent Panel A &B-HMVEC sus-
pensions were pre-treated with buffer (no inhib.) or inhibitors FPT III (100 µM) and control GGTI (2 µM) for 45 min at room 
temperature prior to stimulation with HGF with no ECM proteins, or HGF plus collagen-1 or HGF-FN complexes for 60 min 
at room temperature. Cells were pelleted and lysed in an ice-cold lysis buffer. Samples were analysed by SDS-PAGE and West-
ern blotting probing for phospho Erk 1/2 (panel A) and phospho AKT (panel B). The relative band intensities measured by 
image analysis software have been placed above each band as a ratio of the signal obtained in the sample where no inhibitor 
was present. Blots were stripped and re-probed with antibodies to Erk 2 and Akt to confirm equal loadings. Panel C-HMVEC 
suspensions (5 × 106/ml) were incubated with either FN or collagen in the presence or absence of HGF as shown for 60 min at 
room temperature. Cells were pelleted and lysed in lysis buffer. Immunoprecipitation analyses of the lysates were performed 
with antibodies to integrins α5β1 and α2β1 and the immune complexes analysed by SDS-PAGE and Western blotting probing 
with antibodies to Ras. Visualization was by chemiluminescence.BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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of signals emanating from the ECM. These observations
have led us to propose a model for the mechanisms of
HGF-induced responses in endothelial cells (Fig. 9). This
model shows that HGF alone can induce endothelial cell
proliferation through its receptor Met via activation of the
Ras-Erk kinase pathway (Fig. 9A). However, this signal is
insufficient to promote significant cell migration for
which an additional signal(s) from the ECM via specific
integrin ligation appears necessary for activation of the PI-
3 kinase pathway (Fig. 9B &9C). Uniquely, in cells stimu-
lated with HGF-FN or HGF-VN complexes, which pro-
motes the association of Met with integrins, an enhanced
and unique intracellular signal is generated by the recruit-
ment and sustained activation of Ras, which presumably,
concomitantly activates both p85 PI-3 kinase and Raf (Fig.
9C). This is in contrast to the mechanism of activation of
the PI-3 kinase pathway induced by HGF in the presence
of collagen-1, which is Ras independent (Fig. 9B).
The model in Fig. 9C is supported by the following obser-
vations. The enhanced responses of HMVEC to HGF-FN
and HGF-VN complexes is consistent with the observation
that in these cells the activity of Ras, PI-3 kinase (AKT
phosphorylation) and Erk 1/2 phosphorylation were sus-
Mechanisms of HGF induced cellular responses in endothelial cells Figure 9
Mechanisms of HGF induced cellular responses in endothelial cells. Panel A-HGF in the absence of ECM molecules 
can activate the Map kinase pathway through the Met receptor tyrosine kinase leading to a proliferative response. Panel B-HGF 
and co-stimulation with collagen induces activation of both the Map kinase and PI-3 kinase pathways through an unknown 
mechanism presumably through integrin ligation, which is Ras independent. Panel C-HGF-FN (and by analogy HGF-VN) com-
plexes promote enhanced cellular responses by promoting the association of integrins with the Met receptor leading to the 
recruitment and enhanced activation of Ras, Erk 1/2 kinases and PI-3 kinase promoting both elevated proliferative and migra-
tory responses.BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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tained, and in the case of Ras and Akt, were 2–3 fold
higher than observed in cells stimulated with HGF and
collagen-1 (Fig. 6). The distinct signalling mechanisms
induced by the co-activation of endothelial cells with HGF
in the presence of a binding and non-binding ECM
glycoprotein partner was also supported by the observa-
tion that treatment of cells with the inhibitor of Ras far-
nesylation, FPT III, reduced the phosphorylation of both
Erk 1/2 and Akt kinases in cells stimulated with HGF-FN
but not HGF plus collagen-1 (Fig. 8A &8B). Furthermore,
Ras co-precipitated with the integrin α5β1 derived from
endothelial cell lysates stimulated with HGF-FN com-
plexes but not with the integrin α2β1 derived from cells
stimulated with HGF and collagen-1 (Fig. 8C). These
results are consistent with the pioneering work by
Rodriquez-Viciana and colleagues who demonstrated the
regulation of p85 PI-3 kinase by Ras via direct molecular
interaction. It is now known that the regulatory subunit of
all type 1, PI-3 kinases contain a Ras binding domain that
associates with activated Ras (GTP-Ras) [17-20]. There-
fore, our data and model demonstrating the sustained
activation of Ras and PI-3 kinase by stimulation of
endothelial cells with HGF-FN and HGF-VN complexes is
consistent with previous work showing Ras to be a key
regulator of PI-3 kinase. The identity of the Ras subtypes
mediating the regulation of PI-3 kinase in our cell system
is currently under investigation.
The results of the present study both support and extend
our previous observations of the enhanced endothelial
cell migration induced by VEGF-FN molecular complexes
[9]. In that study, VEGF binding domains identified on FN
drove the formation of VEGF-FN complexes that upon
receptor ligation promoted the association of the integrin
α5β1 with VEGFR-2. This co-receptor activation gave rise
to a sustained activation of the Erk kinase activity, which
promoted an enhanced migratory response. Similarly, the
present work has shown that HGF-FN and HGF-VN
molecular complexes induce the formation of Met-
integrin signalling complexes promoting the transduction
of a unique Ras-dependent signal. Several studies have
illustrated the significance of the cooperation between
integrins and growth factor receptor tyrosine kinases in
mediating cellular responses. For example, the prolifera-
tion and migration of fibroblasts in response to PDGF-BB
was enhanced in the presence of VN and was accompa-
nied by the physical association of the αvβ3 integrin with
the PDGF-β receptor [5,7]. Furthermore, it was recently
demonstrated that HGF in combination with FN prolongs
the survival of GM-colony-forming cells [21] and
enhanced the adhesion and motility of MTLn3 breast car-
cinoma cells [22]. In addition, integrins αvβ3 and αvβ5
were shown to be necessary for mediating FGF-2 and
VEGF mediated angiogenesis respectively by the differen-
tial regulation of components of the Erk kinase pathway
[23]. However, the present study extends these observa-
tions and is, to our knowledge, the first description of a
distinct signalling pathway employed by the activity of
growth factor-ECM molecular complexes as opposed to
growth factors and ECM proteins functioning independ-
ently through ligation of their respective receptors. The
identification of a Ras-dependent pathway in endothelial
cells specifically activated with HGF-FN and HGF-VN
complexes as opposed to HGF in the presence of collagen-
1 is significant and correlates with Met-integrin associa-
tion. Although the precise nature of the interaction
between the Met tyrosine kinase and integrins was not
elucidated, the role of Ras in this system appears impor-
tant for the sustained and enhanced activation of the PI-3
kinase and Erk kinase pathways.
In contrast to the migratory signals promoted by VEGF-FN
molecular complexes [9], HGF-FN and HGF-VN com-
plexes induce a response in endothelial cells characterized
by a tight coupling of the PI-3 kinase pathway to cell
migration. Several additional pro-angiogenic mediators
such as sphingosine 1-phosphate and NO, or the activa-
tion of CD40 and Eph B4 receptors by their counter
ligands, promote endothelial cell migration through acti-
vation of the PI-3 kinase pathway [24-28]. In addition,
HGF on its own was shown to stimulate smooth muscle
cell migration in a PI-3 kinase dependent manner [29].
However, the lack of a significant migratory response,
coupled with the absence of Akt phosphorylation
observed in the present study, suggests that in primary
endothelial cells the Met receptor is unable to activate PI-
3 kinase without cooperative signals from the ECM/
integrins. This observation is intriguing bearing in mind
that Met has been shown to activate PI-3 kinase in epithe-
lial cells via recruitment and activation of Gab-1, which
directly interacts with the p85 subunit [30]. Consistent
with our observation of an integrin dependency for signal
transduction, Trusolino et al showed that in carcinoma
cell lines Met induced signals were considerably amplified
as a consequence of its constitutive association with the
integrin  α6β4. Intriguingly, in this system the authors
showed that the role of the integrin α4 subunit was inde-
pendent of extracellular integrin ligation since a truncated
α4 construct lacking its extracellular portion could medi-
ate HGF/Met responses and signals to downstream effec-
tors provided that its ability to recruit the adaptor Shc was
not affected [31]. In contrast, our studies using primary
endothelial cells showed that integrin ligation was essen-
tial for generating a significant migratory signal via PI-3
kinase and in the case of HGF-FN and HGF-VN com-
plexes, for promoting the association of Met with the
integrins α5β1 and αvβ3 respectively. Indeed, Met associa-
tion with the integrins α5β1 and αvβ3 was dependent
upon the activation of both Met and integrins through
ligation of their cognate ligands since tyrosine phosphor-BMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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ylation of Met by HGF alone could not induce integrin
association (Fig. 3C). These observations support the con-
tention of a signalling mechanism requiring the forma-
tion HGF-ECM molecular complexes as a prerequisite for
Met-integrin association and consequent signal
amplifiation as proposed in Fig. 9C. However, the impor-
tance of integrin cytoplasmic domains in recruiting Ras
and Ras-binding partners appears to reflect a common
mechanism of HGF signal transduction between these cel-
lular systems.
Conclusions
The results of the present work demonstrate an important
mechanism by which integrins collaborate with growth
factor receptor tyrosine kinases on endothelial cells and
predict that HGF binding domains on both FN and VN
may play a significant role in promoting wound healing
and post-natal neovascularization. In support of this con-
tention, HGF-FN and HGF-VN complexes were identified
in the supernatants derived from degranulated platelet
suspensions indicating that these complexes do exist in
vivo and may be deposited at sites of vessel perturbation
or injury. This observation is similar to the identification
of VEGF-FN molecular complexes in platelet supernatants
in our previous report [9] and suggests that HGF and
VEGF may act synergistically in vivo. Indeed, recent studies
have shown that HGF synergises with VEGF to promote
capillary-tube assembly in collagen matrices and neovas-
cularization in the rat cornea [11]. Furthermore, HGF pos-
itively regulates VEGF expression and down regulates TSP-
1, an inhibitor of angiogenesis, thereby promoting angio-
genesis [32]. It is noteworthy that the HGF binding
domains for FN were located in the same proteolytic frag-
ments as those of VEGF, namely the N-terminal 70 kDa
and C-terminal 40 kDa fragments. Further studies involv-
ing the fine mapping and characterization of the binding
domains for VEGF and HGF on FN and VN should help
decipher the mechanism of interplay between these
important pro-angiogenic mediators.
Methods
Solid phase assay and Surface Plasmon Resonance 
Analysis (SPR)
ECM proteins and FN peptides were purchased from
Sigma and Gibco and were further purified by gel filtra-
tion and ion exchange chromatography. The assay was
performed as described previously [9]. 125I-HGF (NEN) in
binding buffer (PBS containing 2% BSA) were added to
the microtitre plates and incubated for 30 min at room
temperature (RT) before washing and counting to deter-
mine bound radioactivity. SPR analysis was performed on
the BIAcore X (Biacore Herts UK) as described previously
[9]. HGF (30–500 nM) was injected across the FN 70 kDa
fragment immobilised on a CM5 chip in HEPES saline
(pH 7.4) supplemented with 1 mM MgCl2, 2 mM CaCl2
and the sensograms recorded. The data was analysed by
the ASSAY programme (Biosoft, UK) in order to deter-
mine the EC50 value and Kd.
Migration and proliferation assays
Human dermal microvessel endothelial cells (HMVEC)
were maintained in EBM-2 growth medium (Clonetics
Corp). Migration studies were carried out essentially as
described previously [9] using serum starved Calcein AM-
loaded HMVEC in a modified Boyden chamber assay
using Fluorblok transwell chambers (BD Bioscience) as
described by the manufacturer. Cell migration was
detected by fluorescence measurement (within the lower
chamber compartment). Membranes of transwell cham-
bers were coated with either FN or VN or collagen-1 (10
µg/ml) overnight at 4°C and preliminary experiments
were performed to assess the optimal dosage of both HGF
and ECM protein. With antibody inhibition studies, the
transwell chamber was coated with poly-L-lysine (Sigma)
to facilitate cell attachment to the filters as opposed to
adhesion using ECM glycoproteins. HMVEC were pre-
treated with αvβ3 and α5β1 integrin blocking antibodies
for 30 min at room temperature prior to application to the
upper transwell chamber. The levels of cell adhesion to
ECM-coated transwell filters were determined by allowing
HGF-stimulated HMVEC to adhere to transwells (coated
overnight with ECM glycoprotein (10 µg/ml) and then
blocked by incubation in 3.5 mg/ml BSA in basal culture
medium) for 1 hour at room temperature followed by
extensive washes with basal culture medium. The remain-
ing cells were measured using a fluorescence plate reader
(measuring fluorescence in the upper transwell compart-
ment). For proliferation experiments, cell division was
measure by fluorescence labeling of DNA (CyQuant,
Molecular Probes). HMVEC was plated on poly-D-lysine
coated 48-well plates and cultured overnight in MCDB-
131 medium containing 5% FBS. After washing plates
with PBS, endothelial cells were then cultured in MCDB-
131 medium + 0.1% FBS containing HGF (10 ng/ml) in
the presence or absence of VN, FN or Collagen-1 (10 µg/
ml). Cells incubated for 48 h and HGF/ECM was added
every 24 hours. Cell proliferation was quantified using a
fluorescence plate reader.
Phosphorylation analysis and ras activation
HMVEC were assessed for the activation profiles of Erk1/
2 and Akt using phosphospecific antibodies (Cell Signal-
ling Technology) to Erk (Thr202/Tyr204) and Akt (Ser473)
respectively by Western blotting. These studies were per-
formed with both cells in suspension and with adherent
populations. Cells were grown to 80% confluence and
serum starved for 2 hours prior to harvesting. Cells were
resuspended in serum-free MCDB-131 medium (BioW-
hittaker) supplemented with 0.1% BSA (resuspension
buffer) at a concentration of 1–5 × 106 cells /ml. The cellBMC Cell Biology 2005, 6:8 http://www.biomedcentral.com/1471-2121/6/8
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suspensions were challenged 10 ng/ml HGF supple-
mented with 2 µg/ml collagen-1, or FN or VN for various
durations ranging from 2 to 120 min at room tempera-
ture. Cells were harvested by centrifugation at 4°C and
lysed in 10 mM Tris pH 7.4, 145 mM NaCl supplemented
with 0.1% Triton X-100 and protease inhibitors. For
inhibitor studies, serum-starved HMVEC suspensions
were pre-treated with the inhibitor for 45 min prior to
stimulation with HGF and ECM molecules for a further 60
min at room temperature. The cells were pelleted, washed
in ice-cold resuspension buffer without BSA and lysed in
a lysis buffer containing 1% (v/v) Triton X-100. Cell
lysates were analysed by Western blotting using protocols
specific for the phosphospecific antibodies according to
the manufacturer's recommendations. Blots were cut
along appropriate marker divides and probed with anti-
bodies to phopho Erk 1/2 and Akt (Ser473) (Cell Signaling
Technologies) simultaneously. For GTP-Ras pull down
assays, serum-starved HMVEC were stimulated with HGF
and ECM molecules for a desired time point and the cells
were spun down and washed in ice-cold resuspension
buffer without BSA. Cell pellets were lysed in MLB buffer
(25 mM HEPES pH 7.5, 150 mM NaCl, 1 % Igepal CA-
630, 10% Glycerol, 25 mM NaF, 10 mM MgCl2, 1 mM
EDTA, 1 mM sodium orthovanadate and protease inhibi-
tor cocktail) and 500 µg of cell lysate was mixed with a 10
µl suspension of RBD-Sepharose (Upstate Biotechnology)
for each reaction at 4°C for 60 min. Sepharose beads were
spun down and washed in MLB prior to solubilization
and analysis by Western blotting probing for Ras using a
monoclonal antibody (Upstate Biotechnology). For Ras
inhibition studies cells were pre-incubated with FPT-III
(100 µM) and GGTI (2 µM) (approx 40 × IC50 values) for
45 min at room temperature prior to cell stimulation for
60 min with HGF and ECM.
Met-Integrin immunoprecipitation
Human microvessel endothelial cells (HMVEC) in serum-
free MCDB-131 medium (BioWhittaker) supplemented
with 0.1% BSA were plated on collagen, FN and VN
coated petri dishes in the absence or presence of HGF (50
ng/ml) for 15 min to 1 hour at room temperature. Cells
were then harvested as described previously [9] and
integrin immunoprecipitation was performed with mon-
oclonal antibodies (Chemicon) to α2β1 (clone JBS2), α5β1
(clone JBS5) and αvβ3 clone (LM609). After analysis by
SDS-PAGE and protein transfer, the blot was then probed
with a monoclonal to Met (clone DL-21, Upstate Biotech-
nology) and developed by chemiluminescence. For Met
tyrosine phosphorylation analysis, cells were stimulated
with HGF alone or HGF-FN and HGF-VN complexes for
various time points ranging from 15 mins to 2 hours at
room temperature. Lysed samples were immunoprecipi-
tated with a polyclonal anti-phosphoMet antibody (Cell
Signalling) and the immune complexes analysed by SDS-
PAGE and Western blotting using a monoclonal ant-Met
antibody (Upstate). Met was visualised using chemilumi-
nescence technology (Pierce).
Immunoprecipitation of FN-HGF and VN-HGF complex 
from platelet supernatants
Supernatants from non-stimulated and thrombin-stimu-
lated washed platelet suspensions were prepared as previ-
ously described [9]. Supernatants were
immunoprecipated with an antibody to FN or VN
(Chemicon) or an isotype matched control reagent (IgG).
Following SDS-PAGE and immunoblotting, HGF was
detected with a polyclonal antibody (Santa Cruz) by
chemiluminescent development.
Abbreviations
HGF, hepatocyte growth factor, FN fibronectin, VN vit-
ronectin, Col-1, collagen-1, HMVEC, human microvessel
endothelial cells.
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